Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03707262 · ClinicalTrials.gov registry record · Phase 1

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

A Phase 1 study of Kidney Transplant and Tolerance, sponsored by Jeffrey Veale, MD.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT03707262: Recruiting Phase 1 study of Kidney Transplant and Tolerance, sponsored by Jeffrey Veale, MD.

NCT03707262 is a Phase 1 study of Kidney Transplant and Tolerance that is actively recruiting participants, run by Jeffrey Veale, MD. The registered enrollment target is 15 participants, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03707262, a Phase 1 study of Kidney Transplant and Tolerance, is actively recruiting participants, sponsored by Jeffrey Veale, MD.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines. This study is for kidney transplant recipients who receive a kidney from a sibling donor. The investigational treatment is started after kidney transplant. It begins with a regimen of a drug called rabbit anti-thymocyte globulin (rATG) combined with radiation therapy (known as total lymphoid irradiation, or TLI) to the lymph nodes and spleen. This is followed by an infusion of blood stem cells, which will be donated by the same sibling who donated their kidney. Researchers think that this treatment allows immune cells from the donor and recipient to live side by side, a condition referred to as "mixed chimerism." Mixed chimerism may help create a state of "tolerance" in kidney transplant recipients in which all immunosuppressive medications can be stopped without rejection of the transplanted kidney. This study will test whether (1) the investigational treatment will allow patients to stop immunosuppressive medications after their kidney transplant and (2) if the treatment impacts the rate of kidney rejection and the side effects of immunosuppressive medications.

Primary Outcome

Percentage of subjects free from all immunosuppressive drugs at 12 months after kidney transplantation.

Interventions

  • BIOLOGICAL Donor CD34+ and CD3+ cells

Study Locations (1)

California

  • University of California, Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-11-06
Est. Completion 2026-02
Phase Phase 1
Jeffrey Veale, MD

1 total trials

What NCT03707262 shows while recruiting

NCT03707262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which Donor CD34+ and CD3+ cells is the first listed.

NCT03707262 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03707262 about?

NCT03707262 is a clinical study titled "Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor". The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines. This study is for kidney transplant recipients who receive a kidney from a sibling donor. The investigational trea...

What is the current status of trial NCT03707262?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-11-06. Estimated completion is 2026-02.

What conditions does trial NCT03707262 study?

This clinical trial studies the following conditions: Kidney Transplant, Tolerance, Renal Transplant Rejection.

What interventions are being tested in trial NCT03707262?

The interventions under investigation include: Donor CD34+ and CD3+ cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT03707262?

This trial is sponsored by Jeffrey Veale, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03707262 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03707262's enrollment target sits among peer trials

15 26th of 30 higher than 4 of 30 other Kidney Transplant trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Kidney Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03707262, the US trial registry maintained by the National Library of Medicine. NCT03707262 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.